Eculizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Eculizumab: From Paroxysmal Nocturnal Hemoglobinuria to Cyclic Hematopoiesis
One-Sentence Summary
Eculizumab is a complement C5 inhibitor, originally used to treat paroxysmal nocturnal hemoglobinuria and neuromyelitis optica. The TxGNN model predicts it may be effective for cyclic hematopoiesis (cyclic neutropenia), but no clinical trials and no directly relevant publications currently support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Paroxysmal nocturnal hemoglobinuria; neuromyelitis optica (the Singapore license text has no approved indication wording) |
| Predicted New Indication | Cyclic hematopoiesis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, eculizumab is a monoclonal antibody that inhibits complement protein C5 and blocks terminal complement activation. Its efficacy in complement-driven diseases such as paroxysmal nocturnal hemoglobinuria is established.
The link to cyclic hematopoiesis is weak. Cyclic neutropenia is typically driven by ELANE mutations that disrupt the regulation of neutrophil precursors, not by uncontrolled complement activity. The high TxGNN score is a graph-based prediction only, and no mechanistic or clinical evidence supports it.
The other top-ranked predictions (various congenital neutropenias, adult idiopathic neutropenia, primary immunodeficiency due to p14 deficiency, and primary release disorder of platelets) share this problem. All have scores around 99.9% and no supporting trials. Their mechanisms (neutrophil maturation, chemokine or G-CSF signaling, endosomal function, platelet secretion) are unrelated to terminal complement inhibition.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature directly addresses eculizumab in cyclic hematopoiesis. Literature was retrieved only for lower-ranked predictions, and it does not support them:
- Congenital neutropenia-myelofibrosis-nephromegaly syndrome (rank 4): 20 publications were retrieved, mostly reviews on complement-mediated diseases (PNH, thrombotic microangiopathy, atypical hemolytic uremic syndrome, myasthenia gravis, CD59 deficiency). They appear to have been matched by drug or complement keywords, not disease relevance, and none address this syndrome.
- Primary release disorder of platelets (rank 10): The only publication is a PNH case-based roundtable review (PMID 23271156, 2012), which does not address platelet release disorders.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14226P | Soliris Concentrate for Solution for Infusion 300mg/vial | Infusion, solution concentrate | Not stated in the available registration data |
Cytotoxicity
Not applicable. Eculizumab is not an antineoplastic drug.
Safety Considerations
- Drug Interactions: 4 interactions were identified, all graded Minor. All involve human immunoglobulin G preparations (intravenous, subcutaneous, intramuscular, and intravenous plus subcutaneous).
Please refer to the package insert for warnings and contraindications. These were not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a graph-based model score. There are no clinical trials, no relevant literature, and no plausible link between complement C5 inhibition and the biology of cyclic neutropenia. The retrieved publications concern other complement-mediated diseases and do not support this indication.
To proceed, the following is needed:
- Singapore package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data
- A disease-specific literature search and trial search for eculizumab in cyclic neutropenia
- Preclinical or mechanistic evidence that complement activity contributes to cyclic hematopoiesis
- Route and formulation compatibility assessment for the new indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.